The enthusiasm for activating Nrf2 as a novel approach to treat human diseases, at least non-cardiac disease, remains very high; a number of clinical trials of various phases on Nrf2 activators for treating diseases such as diabetic complications and cancers are still actively ongoing (Al-Sawaf et al., 2015). Here, NFE2L2 is linked to cancer.